AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. ZLAB
  4. [Form 4] Zai Lab Limited American Insider Trading Activity

[Form 4] Zai Lab Limited American Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Zai Lab officer Amado Rafael, who is identified as President and Head of Global Oncology Research and Development, reported a sale of 3,000 American Depositary Shares (ADS) on 08/08/2025. The Form 4 shows the sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 22, 2024. Each ADS represents ten ordinary shares of the issuer.

After the reported transaction, the reporting person directly beneficially owned 42,178 ADS. The filing discloses the per-ADS price for the reported sale as $35.

Il dirigente di Zai Lab Amado Rafael, indicato come Presidente e Responsabile della Ricerca e Sviluppo Oncologico Globale, ha dichiarato la vendita di 3,000 American Depositary Shares (ADS) in data 08/08/2025. Il Modulo 4 riporta che la vendita 猫 stata eseguita ai sensi di un piano di negoziazione Rule 10b5-1 adottato il 22 novembre 2024. Ciascun ADS rappresenta dieci azioni ordinarie dell'emittente.

Dopo l'operazione comunicata, la persona che ha presentato la comunicazione possedeva direttamente 42,178 ADS. La documentazione indica il prezzo per ADS della vendita segnalata pari a $35.

El directivo de Zai Lab Amado Rafael, identificado como Presidente y Jefe de Investigaci贸n y Desarrollo Oncol贸gico Global, inform贸 la venta de 3,000 American Depositary Shares (ADS) el 08/08/2025. El Formulario 4 muestra que la venta se realiz贸 conforme a un plan de negociaci贸n bajo la Regla 10b5-1 adoptado el 22 de noviembre de 2024. Cada ADS representa diez acciones ordinarias del emisor.

Tras la operaci贸n informada, la persona que present贸 la declaraci贸n pose铆a directamente 42,178 ADS. La presentaci贸n revela que el precio por ADS de la venta reportada fue de $35.

Zai Lab鞚� 鞛勳洂 Amado Rafael鞚�(電�) 靷灔 瓴� 旮�搿滊矊 膦呾枒頃� 鞐瓣惮臧滊皽 毂呾瀯鞛愲 頇曥澑霅橂┌, 2025雲� 8鞗� 8鞚�鞐� 3,000 American Depositary Shares(ADS)毳� 毵る弰頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. Form 4鞐愲姅 頃措嫻 毵る弰電� 2024雲� 11鞗� 22鞚� 毂勴儩霅� Rule 10b5-1 瓯半灅瓿勴殟鞐� 霐半澕 鞚措（鞏挫 瓴冹溂搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 臧� ADS電� 氚滍枆須岇偓鞚� 氤错喌欤� 10欤�鞐� 頃措嫻頃╇媹雼�.

氤搓碃霅� 瓯半灅 頉� 氤搓碃鞚胳潃 歆侅爲鞝侅溂搿� 42,178 ADS毳� 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�. 鞝滌稖靹滊鞐愲姅 氤搓碃霅� 毵る弰鞚� 欤茧嫻 臧�瓴╈潉 $35搿� 旮办灛頃橁碃 鞛堨姷雼堧嫟.

Un dirigeant de Zai Lab, Amado Rafael, identifi茅 comme pr茅sident et responsable mondial de la recherche et d茅veloppement en oncologie, a d茅clar茅 la vente de 3 000 American Depositary Shares (ADS) le 08/08/2025. Le formulaire 4 indique que la vente a 茅t茅 effectu茅e conform茅ment 脿 un plan de n茅gociation Rule 10b5-1 adopt茅 le 22 novembre 2024. Chaque ADS repr茅sente dix actions ordinaires de l'茅metteur.

Apr猫s l'op茅ration d茅clar茅e, la personne d茅clarante d茅tenait directement 42 178 ADS. Le dossier pr茅cise le prix par ADS de la vente d茅clar茅e 脿 35 $.

Zai Lab-Manager Amado Rafael, ausgewiesen als Pr盲sident und Leiter der Global Oncology Research and Development, meldete den Verkauf von 3.000 American Depositary Shares (ADS) am 08.08.2025. Das Formular 4 weist aus, dass der Verkauf im Rahmen eines Rule 10b5-1 Trading Plans, der am 22. November 2024 angenommen wurde, erfolgte. Jede ADS steht f眉r zehn Stammaktien des Emittenten.

Nach der gemeldeten Transaktion hielt die meldende Person unmittelbar wirtschaftlich 42,178 ADS. Die Einreichung gibt den Verkaufspreis pro ADS mit $35 an.

Positive
  • Sale executed under a Rule 10b5-1 trading plan adopted on November 22, 2024
  • Clear disclosure of amount sold (3,000 ADS), sale price ($35 per ADS), and post-transaction holdings (42,178 ADS)
Negative
  • None.

Insights

TL;DR: Routine officer sale under a pre-existing 10b5-1 plan; disclosed holdings remain material and clearly reported.

The Form 4 documents a sale of 3,000 ADS at $35 per ADS executed under a Rule 10b5-1 plan adopted on November 22, 2024. The reporting person retains 42,178 ADS post-transaction. This is a straightforward disclosure of insider activity with explicit quantities, price, and the governing trading plan; there is no additional financial data or operational information in the filing to evaluate broader impact on company fundamentals.

TL;DR: Governance practices are followed: the sale was executed under a documented 10b5-1 plan and properly reported on Form 4.

The filing states the transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 22, 2024, which provides an affirmative defense for pre-planned trades. The report identifies the reporting person s an officer (President, Head of Global Oncology R&D) and discloses direct ownership of 42,178 ADS after a 3,000 ADS sale. From a disclosure and compliance standpoint, the form contains the required elements for insider-trading transparency.

Il dirigente di Zai Lab Amado Rafael, indicato come Presidente e Responsabile della Ricerca e Sviluppo Oncologico Globale, ha dichiarato la vendita di 3,000 American Depositary Shares (ADS) in data 08/08/2025. Il Modulo 4 riporta che la vendita 猫 stata eseguita ai sensi di un piano di negoziazione Rule 10b5-1 adottato il 22 novembre 2024. Ciascun ADS rappresenta dieci azioni ordinarie dell'emittente.

Dopo l'operazione comunicata, la persona che ha presentato la comunicazione possedeva direttamente 42,178 ADS. La documentazione indica il prezzo per ADS della vendita segnalata pari a $35.

El directivo de Zai Lab Amado Rafael, identificado como Presidente y Jefe de Investigaci贸n y Desarrollo Oncol贸gico Global, inform贸 la venta de 3,000 American Depositary Shares (ADS) el 08/08/2025. El Formulario 4 muestra que la venta se realiz贸 conforme a un plan de negociaci贸n bajo la Regla 10b5-1 adoptado el 22 de noviembre de 2024. Cada ADS representa diez acciones ordinarias del emisor.

Tras la operaci贸n informada, la persona que present贸 la declaraci贸n pose铆a directamente 42,178 ADS. La presentaci贸n revela que el precio por ADS de la venta reportada fue de $35.

Zai Lab鞚� 鞛勳洂 Amado Rafael鞚�(電�) 靷灔 瓴� 旮�搿滊矊 膦呾枒頃� 鞐瓣惮臧滊皽 毂呾瀯鞛愲 頇曥澑霅橂┌, 2025雲� 8鞗� 8鞚�鞐� 3,000 American Depositary Shares(ADS)毳� 毵る弰頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. Form 4鞐愲姅 頃措嫻 毵る弰電� 2024雲� 11鞗� 22鞚� 毂勴儩霅� Rule 10b5-1 瓯半灅瓿勴殟鞐� 霐半澕 鞚措（鞏挫 瓴冹溂搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 臧� ADS電� 氚滍枆須岇偓鞚� 氤错喌欤� 10欤�鞐� 頃措嫻頃╇媹雼�.

氤搓碃霅� 瓯半灅 頉� 氤搓碃鞚胳潃 歆侅爲鞝侅溂搿� 42,178 ADS毳� 氤挫湢頃橁矊 霅橃棃鞀惦媹雼�. 鞝滌稖靹滊鞐愲姅 氤搓碃霅� 毵る弰鞚� 欤茧嫻 臧�瓴╈潉 $35搿� 旮办灛頃橁碃 鞛堨姷雼堧嫟.

Un dirigeant de Zai Lab, Amado Rafael, identifi茅 comme pr茅sident et responsable mondial de la recherche et d茅veloppement en oncologie, a d茅clar茅 la vente de 3 000 American Depositary Shares (ADS) le 08/08/2025. Le formulaire 4 indique que la vente a 茅t茅 effectu茅e conform茅ment 脿 un plan de n茅gociation Rule 10b5-1 adopt茅 le 22 novembre 2024. Chaque ADS repr茅sente dix actions ordinaires de l'茅metteur.

Apr猫s l'op茅ration d茅clar茅e, la personne d茅clarante d茅tenait directement 42 178 ADS. Le dossier pr茅cise le prix par ADS de la vente d茅clar茅e 脿 35 $.

Zai Lab-Manager Amado Rafael, ausgewiesen als Pr盲sident und Leiter der Global Oncology Research and Development, meldete den Verkauf von 3.000 American Depositary Shares (ADS) am 08.08.2025. Das Formular 4 weist aus, dass der Verkauf im Rahmen eines Rule 10b5-1 Trading Plans, der am 22. November 2024 angenommen wurde, erfolgte. Jede ADS steht f眉r zehn Stammaktien des Emittenten.

Nach der gemeldeten Transaktion hielt die meldende Person unmittelbar wirtschaftlich 42,178 ADS. Die Einreichung gibt den Verkaufspreis pro ADS mit $35 an.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Amado Rafael
(Last) (First) (Middle)
C/O ZAI LAB LIMITED
314 MAIN STREET, 4TH FLOOR, SUITE 100
(Street)
CAMBRIDGE MA 02142
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Zai Lab Ltd [ ZLAB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
American Depositary Shares(1) 08/08/2025 S(2) 3,000 D $35 42,178 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
2. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2024.
Remarks:
President, Head of Global Oncology Research and Development
/s/ Bruce Blefeld, Attorney-in-Fact 08/12/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

Who filed the Form 4 for Zai Lab (ZLAB)?

The Form 4 was filed by Amado Rafael, identified as President and Head of Global Oncology Research and Development.

How many ADS did the reporting person sell and at what price?

The filing reports a sale of 3,000 ADS at a price of $35 per ADS.

Was the transaction part of a 10b5-1 trading plan?

Yes. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 22, 2024.

How many ADS does the reporting person own after the transaction?

After the reported sale, the reporting person directly beneficially owned 42,178 ADS.

What does one ADS represent for Zai Lab?

Each American Depositary Share (ADS) represents ten ordinary shares of Zai Lab, as stated in the filing.
Stock ZLAB logo
Zai Lab Limited

NASDAQ:ZLAB

ZLAB Rankings

#1524 Ranked by Market Cap
N/A Ranked by Dividends

ZLAB Latest News

Aug 13, 2025
Zai Lab Establishes Oncology Scientific Advisory Board
Aug 7, 2025
Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates
Jul 10, 2025
Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025
Jun 30, 2025
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
Jun 13, 2025
Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025

ZLAB Latest SEC Filings

Aug 13, 2025
[144] Zai Lab Limited American SEC Filing
Aug 12, 2025
[Form 4] Zai Lab Limited American Insider Trading Activity
Aug 12, 2025
[Form 4] Zai Lab Limited American Insider Trading Activity
Aug 12, 2025
[144] Zai Lab Limited American SEC Filing
Aug 12, 2025
[SCHEDULE 13G/A] Zai Lab Limited American SEC Filing

ZLAB Stock Data

3.81B
106.54M
1.42%
50.94%
3.61%
Biotechnology
Pharmaceutical Preparations
China
SHANGHAI